Bio Elpida, your CMO for Innovative Cell Therapy
From Development to Logistics and Release of Clinical batches
Bio Elpida is the CMO specialised in the development of cell therapy products and innovative therapy products. The expertise of the company encompasses all the steps from R&D and pharmaceutical development to GMP manufacturing of cell therapy products based on innovative approaches for:
The goal of Bio Elpida is to become the European expert and to bring all its expertise so that these new clinical approaches become a reality for biotechnologies and cell therapy companies and patients.
Cell therapy: a new medical approach that ought to reach the marketCell Therapy is part of a new approach defined by EMEA as "Advanced Therapeutic Medicinal Product", which could be an alternative or a complementary treatment to existing and more traditional therapies.
Cell therapy involves cells and tissues to heal and/or repair part of the human body. Regenerative medicine is part of the cell therapy and aims at achieving effective, long-term treatments for chronic diseases involving tissue and/or organ damages.
There are different ways to performing cell therapy:
- Autologous cell therapy uses the patient's own cells; a biopsy is taken, the cells are manipulated and expanded in the lab, and then returned to the patient. Conducting autologous cell therapy on a commercial-scale involves "scaling out" rather than scaling up; it is similar to existing procedures, such as blood transfusion, and may fit as a "bedside" procedure in the healthcare system.
- Allogeneic cell therapy uses donor cells sourced from genetically dissimilar individuals and used as a source of therapy. Allogeneic cell therapy is more akin to conventional (bio) pharmaceuticals.
- Cell therapy using cultured cells from defined cell lines or from expansion of the patient cells.
Bio Elpida aims at becoming the European expert and providing all its knowledge and expertise in order to make this new medical approach real for biotech companies and patients.